SATISFYNCT05935202
Safety and Efficacy of Mitapivat Sulfate in Adult Patients With Erythrocyte Membranopathies
At risk: Primary completion moved at least 3 years 2 months later.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 4 versions: 3 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Primary completion pushed from Jul 15, 2025 to Sep 30, 2028 Show 6 more changesShow less
- Eligibility criteria expanded, about 40 words
- Trial status changed: Not Yet Recruiting → Active, Not Recruiting
- Study completion pushed from Dec 15, 2026 to Mar 30, 2029
- Secondary endpoints: details revised at 1 of 1 entry
- Site details revised at 2 of 2 sites
- Publications: details revised at 1 of 1 entry
- Notable Start date: Sep 15, 2023 to Dec 21, 2023
- Study description expanded, about 36 words
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Secondary (1)
Arms and interventions
subjects who enter the Dose Escalation Period will receive an initial dose of 50 mg mitapivat BID. After 4 weeks dose will be increased from 50 mg BID to 100 mg BID unless dose-limiting side effects have occurred or maximum allowed Hb levels have been reached. Subjects who safely tolerate mitapivat may be eligible to continue in two consecutive 24-week Fixed Dose Periods, allowing patients to remain on their tolerated dose of mitapivat for up to 48 weeks after dose escalation. During the Fixed Dose Periods, the dose may not exceed the maximum dose that was used during Dose Escalation Period. 8 weeks: Dose Escalation Period 24-week: Fixed Dose Period 1 24-week: Fixed Dose Period 2
Drugs: Mitapivat sulfate
Sites
2 sites in 2 countries
Denmark 1, Netherlands 1